Autopsy report · NCT00448240

Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer

“Low Accrual, Funding”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 4 years 11 months before it stopped.
• 6 participants enrolled.
• Results were posted on the registry 13 years 2 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2, Phase 3

Sponsor

Henry Ford Health System

Sponsor type

University, hospital or other

Conditions

Head and Neck Cancer; Carcinoma, Squamous Cell

Interventions

Erlotinib

Participants

6

Trials that died the same way

• Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer
  “Low accrual/Loss of funding” (90% match in meaning)
• Response-Adapted Omission of Nodal Boost In N3 Breast Cancer After Neoadjuvant Therapy
  “funding issues and poor accrual” (87% match in meaning)
• Prehabilitation With Aerobic and Resistance Exercise for Improving Physical Fitness and Quality of Life Outcomes in Older Patients Undergoing CAR-T Therapy for Relapsed or Refractory Multiple Myeloma
  “Limited funding, slow accrual” (83% match in meaning)
• Quantitative Imaging Biomarkers of Treatment Response in Osteosarcoma and Ewing Sarcoma
  “Slow accrual and lack of funding” (81% match in meaning)
• Pharmacology of Antimalarial Therapy With or Without Antiretroviral Therapy
  “Slow accrual and funding limitations.” (80% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.